166 research outputs found
CATHETER ABLATION OF WOLFF-PARKINSON WHITE SYNDROME: 14-YEAR TRENDS IN UTILIZATION AND COMPLICATIONS IN THE UNITED STATES
CRT-710 Associations Of Known Complications With Transcatheter Implantation Of First-generation Self Expandable Corevalve Aortic Valves With Peri-procedural Mortality-an Insight From Reports From The FDA Maude Database
ATTRIBUTABLE RISK ESTIMATE OF SEVERE PSORIASIS ON MAJOR CARDIOVASCULAR EVENTS
Le principal défi du CTA est de faire face à la rapide mutation du milieu dans lequel nous travaillons : nous adapter à l’évolution fulgurante des technologies de l’information et de la communication (TIC) et, en réponse à certains des paradigmes du développement qui ont mal vieilli, identifier de nouveaux modèles et des mécanismes novateurs répondant aux besoins actuels de développement.
En 2006, nous nous sommes démarqués de l’approche “business as usual”. Nous avons introduit quelques changements dans notre gestion et notre culture organisationnelle et, par là même, dans notre état d’esprit.
Dr. Hansjörg Neun
Directeur, CTALe principal défi du CTA est de faire face à la rapide mutation du milieu dans lequel nous travaillons : nous adapter à l’évolution fulgurante des technologies de l’information et de la communication (TIC)... Dr. Hansjörg NeunDirecteur, CT
Predictors of in-hospital mortality in coronary artery dissection: Findings from the National Inpatient Sample 2009–2010
Background: The pathophysiology of coronary artery dissection (CD) remains poorly underÂstood and little is known about the factors predicting mortality in these patients. We aimed to study the epidemiology of CD and predictors of mortality in these patients.
Methods: All patients diagnosed with CD in the Nationwide Inpatient Sample 2009–2010 database using International Classification of Diseases ninth revision 414.12 were included in the study. Chronic conditions included in the analysis were diabetes mellitus, hypertension, hyperlipidemia, coronary artery disease (CAD), obesity, alcohol use, smoking, heart failure and ventricular arrhythmias. Non-cardiovascular conditions were connective tissue disorders, fibromuscular dysplasia, Ehlers-Danlos syndrome, Marfan’s syndrome, sarcoidosis, Crohn’s disease, polycystic kidney disease, rheumatoid arthritis, vasculitis including giant cell arteritis, polyarteritis nodosa and Takayasu’s disease, cocaine use, early or premature labor.
Results: The prevalence of CD in the United States was 0.02% (n = 11,255), based on the hospital admissions reviewed in the database. The mean age was 63.25 years with women (64.62 years) being older than men (62.25 years) (p < 0.001). In-hospital mortality rate was 4.2%, with women (5.5%) having higher mortality than men (3.2%) (p = 0.009). Ventricular arrhythmias (OR 5.86, p < 0.001) predicted higher mortality, while hyperlipidemia (OR 0.26, p < 0.001) and CAD (OR 0.31, p = 0.001) predicted lower mortality in multivariate analysis.
Conclusions: Our study demonstrated that CD was more prevalent in men but women had higher mortality than men. Age, heart failure and ventricular arrhythmias were independent predictors of increased mortality but hyperlipidemia CAD predicted lower mortality in patients with CD
Safety Of Uninterrupted Periprocedural Apixaban In Patients Undergoing Atrial Fibrillation Catheter Ablation: A Metaanalysis Of 1,057 Patients
Role Of Prophylactic Magnesium Supplementation in Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Grafting: A Meta-analysis of 23 Randomized Controlled Trials (Poster).
Background Several randomized clinical trials have evaluated the efficacy of prophylactic magnesium (Mg) supplementation in prevention of post-operative atrial fibrillation (POAF) in patients undergoing cardiac artery bypass grafting (CABG). We aim to determine the role of prophylactic Mg in 3 settings (intraoperative, postoperative, intraoperative + postoperative) in prevention of POAF. Methods A systemic literature search was performed (until October 20, 2015) using PubMed, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials to identify trials evaluating Mg supplementation post CABG. Primary outcome of our study was reduction in the POAF. For each study, the incidence of atrial fibrillation in both the intervention and placebo groups was extracted to calculate odd ratio and 95% confidence intervals (CIs). Results We included a total of 2,973 participants (1,471 in the Mg group and 1,502 in the placebo group) enrolled in 23 randomized controlled trials. By using random-effects models, pooled analysis demonstrated no significant reduction in POAF (OR 0.81; 95% CI, 0.64-1.02; p = 0.08) in Mg group as compared to placebo. However, there was reduction in POAF in the group that received prophylactic Mg postoperatively (OR 0.66; 95% CI 0.44-0.99; p = 0.04) with no significant heterogeneity. Number needed to treat in our study = 13 (95% CI 7.04-81.34). Conclusions Prophylactic postoperative Mg supplementation resulted in a lower incidence of POAF in patients undergoing CABG
VASCULAR INFLAMMATION BY [18F]-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY IS ASSOCIATED WITH AORTIC WALL PROPERTIES BY MAGNETIC RESONANCE IMAGING
DIRECTLY MEASURED INFLAMMATION IN PSORIASIS SKIN ASSOCIATES WITH VASCULAR INFLAMMATION BEYOND TRADITIONAL RISK FACTORS
Higher plasma CXCL12 levels predict incident myocardial infarction and death in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort study
Aims
Genome-wide association studies revealed an association between a locus at 10q11, downstream from CXCL12, and myocardial infarction (MI). However, the relationship among plasma CXCL12, cardiovascular disease (CVD) risk factors, incident MI, and death is unknown. Methods and Results
We analysed study-entry plasma CXCL12 levels in 3687 participants of the Chronic Renal Insufficiency Cohort (CRIC) Study, a prospective study of cardiovascular and kidney outcomes in chronic kidney disease (CKD) patients. Mean follow-up was 6 years for incident MI or death. Plasma CXCL12 levels were positively associated with several cardiovascular risk factors (age, hypertension, diabetes, hypercholesterolaemia), lower estimated glomerular filtration rate (eGFR), and higher inflammatory cytokine levels (P \u3c 0.05). In fully adjusted models, higher study-entry CXCL12 was associated with increased odds of prevalent CVD (OR 1.23; 95% confidence interval 1.14, 1.33, P \u3c 0.001) for one standard deviation (SD) increase in CXCL12. Similarly, one SD higher CXCL12 increased the hazard of incident MI (1.26; 1.09,1.45, P \u3c 0.001), death (1.20; 1.09,1.33, P \u3c 0.001), and combined MI/death (1.23; 1.13–1.34, P \u3c 0.001) adjusting for demographic factors, known CVD risk factors, and inflammatory markers and remained significant for MI (1.19; 1.03,1.39, P = 0.01) and the combined MI/death (1.13; 1.03,1.24, P = 0.01) after further controlling for eGFR and urinary albumin:creatinine ratio. Conclusions
In CKD, higher plasma CXCL12 was associated with CVD risk factors and prevalent CVD as well as the hazard of incident MI and death. Further studies are required to establish if plasma CXCL12 reflect causal actions at the vessel wall and is a tool for genomic and therapeutic trials
MONOCYTE SUBSETS PREDICT VASCULAR INFLAMMATION BEYOND TRADITIONAL RISK FACTORS OF CARDIOVASCULAR DISEASE IN PSORIASIS
- …